← Back to Search

Electrical Continence Device

Monitoring during activation of the FemPulse System for Overactive Bladder

N/A
Waitlist Available
Research Sponsored by FemPulse Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 hours
Awards & highlights

Summary

The purpose of this feasibility clinical investigation is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Autonomic nervous system response
Evoked Potential response

Trial Design

1Treatment groups
Experimental Treatment
Group I: Monitoring during activation of the FemPulse SystemExperimental Treatment1 Intervention
Subjects will undergo non-invasive monitoring during activation of the FemPulse System.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
The FemPulse System
2019
N/A
~10

Find a Location

Who is running the clinical trial?

FemPulse CorporationLead Sponsor
3 Previous Clinical Trials
56 Total Patients Enrolled
~0 spots leftby Sep 2025